PMID: 15220224Jun 29, 2004Paper

The burden of treatment failure in type 2 diabetes

Diabetes Care
Jonathan B BrownAndrew Perry

Abstract

In type 2 diabetes, therapies to maintain blood glucose control usually fail after several years. We estimated the glycemic burden that accumulates from treatment failure and describe the time course and predictors of failure. A prospective, population-based study using retrospective observational data. We identified all 7208 complete courses of treatment with nondrug therapy, sulfonylurea monotherapy, metformin monotherapy, and combination oral antihyperglycemic therapy between 1994 and 2002, inclusive, among members of the Kaiser Permanente Northwest Region. We calculated mean cumulative glycemic burden, defined as HbA(1c)-months >8.0 or 7.0% for each treatment. We then measured the likelihood that the next HbA(1c) would exceed 8.0 and 7.0% after HbA(1c) exceeded each of ten hypothetical treatment thresholds. Finally, we estimated multivariate logistic regression models to predict when HbA(1c) would continue to deteriorate. In this well-controlled population, the average patient accumulated nearly 5 HbA(1c)-years of excess glycemic burden >8.0% from diagnosis until starting insulin and about 10 HbA(1c)-years of burden >7.0%. Whenever patients crossed the American Diabetes Association-recommended treatment threshold of 8.0%, t...Continue Reading

References

Sep 30, 1993·The New England Journal of Medicine·UNKNOWN Diabetes Control and Complications Trial Research GroupC Siebert
Feb 29, 2000·The Western Journal of Medicine·J B BrownH S Glauber
Sep 15, 2000·The Western Journal of Medicine·G A NicholsJ B Brown
Nov 18, 2000·Diabetes Research and Clinical Practice·J B BrownA Russell
Dec 28, 2002·Diabetes Care·UNKNOWN Expert Committee on the Diagnosis and Classification of Diabetes Mellitus
Dec 28, 2002·Diabetes Care·UNKNOWN American Diabetes Association

❮ Previous
Next ❯

Citations

Mar 21, 2007·Journal of General Internal Medicine·Gregory A NicholsSonali N Shah
Apr 29, 2010·Current Diabetes Reports·Edward S Horton
Mar 17, 2009·Advances in Therapy·Abd A TahraniAnthony H Barnett
May 8, 2010·Advances in Therapy·Edith M HeintjesRon M C Herings
Jan 25, 2012·Advances in Therapy·Lawrence Blonde, Zinnia T San Juan
Jun 21, 2012·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Stephan MatthaeiMichael Theodorakis
Jul 25, 2013·Diabetes Therapy : Research, Treatment and Education of Diabetes and Related Disorders·Joel M NeutelChetan S Karyekar
Oct 18, 2005·The American Journal of Medicine·John E Gerich
Jun 28, 2006·Nature Reviews. Drug Discovery·David R OwensPeter Kirkpatrick
Oct 26, 2005·Diabetes Technology & Therapeutics·M Arthur Charles
Aug 22, 2008·Diabetes Technology & Therapeutics·Stephen Brunton
Jun 22, 2013·Diabetes Technology & Therapeutics·David R Owens
Dec 1, 2007·JAAPA : Official Journal of the American Academy of Physician Assistants·John Leahy
Mar 21, 2009·Current Opinion in Endocrinology, Diabetes, and Obesity·Mayer B Davidson
Jul 23, 2008·American Journal of Therapeutics·Valmore BermúdezRafael Hernández
Mar 3, 2007·Southern Medical Journal·Luigi Meneghini
Jul 17, 2008·Diabetes, Obesity & Metabolism·S A Schreiber
Apr 13, 2010·Diabetes, Obesity & Metabolism·Kevin Niswender
Oct 1, 2010·Diabetes, Obesity & Metabolism·E E WrightR M Cuddihy
Mar 21, 2012·Diabetes, Obesity & Metabolism·M A Nauck
Oct 21, 2005·International Journal of Clinical Practice·S Del PratoUNKNOWN Global Partnership for Effective Diabetes Management
Dec 6, 2007·International Journal of Clinical Practice. Supplement·K G M M AlbertiUNKNOWN Global Partnership for Effective Diabetes Management
Apr 9, 2008·International Journal of Clinical Practice·R P HayesS J Jacober
Jul 3, 2009·International Journal of Clinical Practice·J Ross MacleanG Krishnarajah
Feb 15, 2011·International Journal of Clinical Practice·C J Bailey, M Kodack

❮ Previous
Next ❯